Regulatory Affairs Industry News Roundup – June 2017
It has been a busy month at Acorn Regulatory. Here is a recap of the top regulatory affairs industry news stories for the past month. Remember, you can subscribe to our monthly newsletter here and have all of the top Acorn...
Pharmaceutical Regulatory Affairs News – May 2017
It has been a busy month at Acorn Regulatory. Here is a recap of the top pharmaceutical regulatory affairs news stories for the past month. Remember, you can subscribe to our monthly newsletter here and have all of the top Acorn...
Acorn Regulatory NewsAcorn Regulatory's Top 100 ArticlesChristine McGrathPharmaceuticalQuality Management System
A New Approach to The Pharmaceutical Quality System
Is your quality system keeping pace with the changes in manufacturing technology and new thinking in how manufacturing companies approach the issues of quality? Many companies have adopted the pharmaceutical quality system outlined in ICH Q10 and experienced the benefits...
Acorn Regulatory NewsAcorn Regulatory's Top 100 ArticlesAdvertisingComplianceGemma RobinsonPharmaceutical
Advertising of Medicinal Products – An Overview
Advertising of medicinal products in Ireland is governed by a statutory instrument (S.I.) 541/2007, which transposes into Irish law Titles VIII and VIIIa of Directive 2001/83/EC (as amended by Directive 2004/27/EC). We look at the issues relating to advertising a...
The Implications of Brexit for the Life Sciences Sector
The implications of Brexit are still being felt. Politically, the decision has triggered a chain of events that none of us could have ever foreseen. Now, with a new Prime Minister in Downing Street and three leading ‘Brexiteers’ appointed to offices...
Brexit: The Implications on Existing Marketing Authorisations
In this extract from our first Brexit whitepaper we look at the implications of Brexit for existing marketing authorisations.
By using this website, you agree to our
cookie policy.
Close